Compare ANNX & PD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ANNX | PD |
|---|---|---|
| Founded | 2011 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Prepackaged Software |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 730.4M | 636.9M |
| IPO Year | 2020 | 2019 |
| Metric | ANNX | PD |
|---|---|---|
| Price | $5.87 | $5.73 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 9 |
| Target Price | ★ $16.50 | $12.63 |
| AVG Volume (30 Days) | 2.4M | ★ 2.8M |
| Earning Date | 05-11-2026 | 05-28-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 416.95 |
| EPS | N/A | ★ 1.87 |
| Revenue | N/A | ★ $492,546,000.00 |
| Revenue This Year | N/A | $3.58 |
| Revenue Next Year | $22,605.10 | $2.88 |
| P/E Ratio | ★ N/A | $3.26 |
| Revenue Growth | N/A | ★ 5.36 |
| 52 Week Low | $1.40 | $5.82 |
| 52 Week High | $7.18 | $17.45 |
| Indicator | ANNX | PD |
|---|---|---|
| Relative Strength Index (RSI) | 55.27 | 29.27 |
| Support Level | $4.79 | N/A |
| Resistance Level | $6.50 | $16.47 |
| Average True Range (ATR) | 0.44 | 0.36 |
| MACD | 0.09 | 0.01 |
| Stochastic Oscillator | 66.67 | 2.84 |
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.
PagerDuty Inc is a digital operations management platform that manages urgent and mission-critical work for a modern, digital business. Its PagerDuty Operations Cloud combines artificial intelligence (AI) operations (AIOps), automation, customer service operations, and incident management with a generative AI assistant to create a flexible, resilient, and scalable platform to protect revenue and improve customer experience, improve operational efficiency, and mitigate the risk of operational failures. The company generates revenue predominantly from cloud-hosted software subscription fees and term-license software subscription fees. Geographically, the firm derives a majority of its revenue from the United States and the rest from International markets.